Marizyme Inc (MRZM) Stock Price, Trades & News

Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History
	FCF Margin %	-2032.07
	OCF Margin %	-2032.07

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History

Financials (Next Earnings Date:2026-07-06 Est.)

Annual Quarterly TTM

MRZM's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:MRZM

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Marizyme Inc Executives

Details

GF Value™

MRZM

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with MRZM. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	0.184
	EPS (TTM) ($)	-0.11
	Beta	1.896
	3-Year Sharpe Ratio	0.25
	3-Year Sortino Ratio	0.84
	Volatility %	-
	14-Day RSI	-
	14-Day ATR ($)	-
	20-Day SMA ($)	0.0003
	12-1 Month Momentum %	-
	52-Week Range ($)	0.0003 - 0.0003
	Shares Outstanding (Mil)	131.79

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Marizyme Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Marizyme Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings results for 2026	2026-11-13	In 130 days
Second quarter earnings results for 2026	2026-08-14	In 39 days
General meeting for 2025	2026-07-27	In 21 days
Annual report for 2025	2026-07-06	--
First quarter earnings results for 2026	2026-07-06	--
Third quarter earnings results for 2024	2025-03-07	0.05 (+0.00%)
Second quarter earnings results for 2024	2024-08-14	0.03 (+0.00%)
0.034483:1 Stock Split	2018-07-27	1.45 (+0.00%)

Show

Entries

Marizyme Inc Frequently Asked Questions

What is Marizyme Inc(MRZM)'s stock price today?

The current price of MRZM is $0.00. The 52 week high of MRZM is $0.00 and 52 week low is $0.00.

When is next earnings date of Marizyme Inc(MRZM)?

The next earnings date of Marizyme Inc(MRZM) is 2026-07-06 Est..

Does Marizyme Inc(MRZM) pay dividends? If so, how much?

Marizyme Inc(MRZM) does not pay dividend.

Guru Commentaries on OTCPK:MRZM

No articles.

Press Release

	Subject	Date
	The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News	2023-10-06
	Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera	2021-03-04
	Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board	2021-02-04
	Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems	2021-02-01
	Marizyme Announces Approval for DuraGraft® in India	2021-01-14
	Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf	2021-01-11
	Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"	2021-01-07
	Marizyme, Inc. Expands Executive Team, Board of Directors	2020-12-04
	Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors	2020-11-06
	Marizyme and SBH Nutrition Science Agree to Develop Krillase(R) Based Dental Products for Pets	2020-10-27

10/Page

Articles on Marizyme Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.